Oral Bacteria May Diagnose Pancreatic Cancer
|
By LabMedica International staff writers Posted on 04 Jun 2014 |

Image: The anaerobic bacteria Leptotrichia species, Gram-stain from blood culture (Photo courtesy of Mike Dyall-Smith).
Patients with pancreatic cancer have a different and distinct profile of specific bacteria in their saliva compared to healthy controls and even patients with other cancers or pancreatic diseases.
Patients diagnosed in the early stages of pancreatic cancer have a 5-year survival rate of 21.5%, but unfortunately symptoms do not appear until after the cancer has become untreatable in the vast majority of cases.
Scientists from San Diego State University (CA, USA) compared the diversity of saliva bacteria across 131 patients, 63 females and 68 males, being treated at the University of California, San Diego (UCSD) Moores Cancer Center (La Jolla, CA, USA). Of these patients, 14 had been diagnosed with pancreatic cancer, 13 with pancreatic disease, 22 with other forms of cancer, and 10 were disease free.
The results of the study found that patients diagnosed with pancreatic cancer had higher levels of two particular oral bacteria, Leptotrichia and Campylobacter, when compared to any other healthy or diseased state including noncancerous pancreatic disease. Those with pancreatic cancer also had lower levels of Streptococcus, Treponema, and Veillonella. These findings could form the basis for a test to diagnose the pancreatic cancer in its early stages.
Pedro Torres, BS, the coauthor of the study with Scott T. Kelley, PhD, said, “Our studies suggest that ratios of particular types of bacteria found in saliva may be indicative of pancreatic cancer. The results also suggest the presence of a consistently distinct microbial profile for pancreatic cancer. We may be able to detect pancreatic cancer at its early stages by taking individuals’ saliva and looking at the ratios of these bacteria.”
In the USA, approximately 40,000 people die every year due to pancreatic adenocarcinoma, making it the fourth leading cause of cancer related death. The study was presented on May 18, 2014, at the Annual meeting of the American Society for Microbiology held May 17–20, 2014, in Boston (MA, USA).
Related Links:
San Diego State University
Moores Cancer Center
Patients diagnosed in the early stages of pancreatic cancer have a 5-year survival rate of 21.5%, but unfortunately symptoms do not appear until after the cancer has become untreatable in the vast majority of cases.
Scientists from San Diego State University (CA, USA) compared the diversity of saliva bacteria across 131 patients, 63 females and 68 males, being treated at the University of California, San Diego (UCSD) Moores Cancer Center (La Jolla, CA, USA). Of these patients, 14 had been diagnosed with pancreatic cancer, 13 with pancreatic disease, 22 with other forms of cancer, and 10 were disease free.
The results of the study found that patients diagnosed with pancreatic cancer had higher levels of two particular oral bacteria, Leptotrichia and Campylobacter, when compared to any other healthy or diseased state including noncancerous pancreatic disease. Those with pancreatic cancer also had lower levels of Streptococcus, Treponema, and Veillonella. These findings could form the basis for a test to diagnose the pancreatic cancer in its early stages.
Pedro Torres, BS, the coauthor of the study with Scott T. Kelley, PhD, said, “Our studies suggest that ratios of particular types of bacteria found in saliva may be indicative of pancreatic cancer. The results also suggest the presence of a consistently distinct microbial profile for pancreatic cancer. We may be able to detect pancreatic cancer at its early stages by taking individuals’ saliva and looking at the ratios of these bacteria.”
In the USA, approximately 40,000 people die every year due to pancreatic adenocarcinoma, making it the fourth leading cause of cancer related death. The study was presented on May 18, 2014, at the Annual meeting of the American Society for Microbiology held May 17–20, 2014, in Boston (MA, USA).
Related Links:
San Diego State University
Moores Cancer Center
Latest Pathology News
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
- AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
- Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
- AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
- New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
- Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
- Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
- Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more
Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak.... Read more
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more
Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more








